Drug intelligence / Profile preview

Fematin

Development stage: Unknown
Lead developer: Cho-A Pharm
Modality: Recombinant Proteins and Enzymes
Administration: Oral

Overview

Fematin (also known as Fematin-A) is an over-the-counter (OTC) hematopoietic nutritional product developed and marketed by Cho-A Pharmaceutical in South Korea. The product contains ferritin extractive hydroglyceric as its active ingredient, which provides a bioavailable source of iron bound to the ferritin protein. Ferritin is the body's primary iron-storage protein, and its supplementation is intended to support hematosis (blood formation) and treat or prevent iron deficiency and anemia. Fematin is available in oral liquid formulations, including 10ml ampoules and syrup, and is a core product in Cho-A Pharmaceutical's portfolio of internal ampoule medicines distributed through pharmacies.

Brand names: FematinFematin-A
Other names: ferritin extractive hydroglyceric

Beyond the preview

Go deeper on Fematin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fematin.

Explore the full profile